1
|
Chen Y, Chen Y, Liu W. Chaperonin containing TCP1 subunit 6A may activate Notch and Wnt pathways to facilitate the malignant behaviors and cancer stemness in oral squamous cell carcinoma. Cancer Biol Ther 2024; 25:2287122. [PMID: 38084868 PMCID: PMC10761149 DOI: 10.1080/15384047.2023.2287122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 11/20/2023] [Indexed: 12/18/2023] Open
Abstract
Chaperonin containing TCP1 subunit 6A (CCT6A) was recently discovered to be involved in cancer pathogenesis and stemness; however, its role in oral squamous cell carcinoma (OSCC) has not been reported. The current study aimed to investigate the impact of CCT6A on OSCC cell malignant behaviors and stemness and to explore its potentially interreacted pathways. SCC-15 and HSC-3 cells were transfected with the plasmid loading control overexpression, CCT6A overexpression, control knockout, or CCT6A knockout. Wnt4 overexpression or Notch1 overexpression plasmids were transfected into CCT6A-knockout SCC-15 cells. Cell proliferation, apoptosis, invasion, stemness, Notch, and Wnt pathways were detected in both cell lines, whereas RNA sequencing was only performed in SCC-15 cells. CCT6A was upregulated in five OSCC cell lines, including SCC-15, HSC-3, SAT, SCC-9, and KON, compared to that in the control cell line. In SCC-15 and HSC-3 cells, CCT6A overexpression increased cell proliferation, invasion, sphere formation, CD133, and Sox2 expression, but decreased cell apoptosis; on the contrary, CCT6A knockout exhibited an opposite effect on the above indexes. RNA-sequencing data revealed that the Wnt and Notch pathways were involved in the CCT6A'effect on SCC-15 cell functions. CCT6A positively regulates the Wnt and Notch pathways in SCC-15 and HSC-3 cells. Importantly, it was shown that activation of the Wnt or Notch pathways attenuated the effect of CCT6A knockout on SCC-15 cell survival, invasion, and stemness. CCT6A may promote OSCC malignant behavior and stemness by activating the Wnt and Notch pathways.
Collapse
Affiliation(s)
- Yangyi Chen
- Department of Oral and Maxillofacial Surgery, Shengjing Hospital of China Medical University, Shenyang, China
| | - Yongge Chen
- Department of Oncology, Handan Central Hospital, Handan, China
| | - Weixian Liu
- Department of Oral and Maxillofacial Surgery, Shengjing Hospital of China Medical University, Shenyang, China
| |
Collapse
|
2
|
Tang S, Wang Q, Sun K, Song Y, Liu R, Tan X, Li H, Lv Y, Yang F, Zhao J, Li S, Bi P, Yang J, Zhu Z, Chen D, Chuan Z, Luo X, Hu Z, Liu Y, Li Z, Ke T, Jiang D, Zheng K, Yang R, Chen K, Guo R. Metabolic Heterogeneity and Potential Immunotherapeutic Responses Revealed by Single-Cell Transcriptomics of Breast Cancer. Apoptosis 2024:10.1007/s10495-024-01952-7. [PMID: 38578322 DOI: 10.1007/s10495-024-01952-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/02/2024] [Indexed: 04/06/2024]
Abstract
BACKGROUND Breast cancer (BC) exhibits remarkable heterogeneity. However, the transcriptomic heterogeneity of BC at the single-cell level has not been fully elucidated. METHODS We acquired BC samples from 14 patients. Single-cell RNA sequencing (scRNA-seq), bioinformatic analyses, along with immunohistochemistry (IHC) and immunofluorescence (IF) assays were carried out. RESULTS According to the scRNA-seq results, 10 different cell types were identified. We found that Cancer-Associated Fibroblasts (CAFs) exhibited distinct biological functions and may promote resistance to therapy. Metabolic analysis of tumor cells revealed heterogeneity in glycolysis, gluconeogenesis, and fatty acid synthetase reprogramming, which led to chemotherapy resistance. Furthermore, patients with multiple metastases and progression were predicted to benefit from immunotherapy based on a heterogeneity analysis of T cells and tumor cells. CONCLUSIONS Our findings provide a comprehensive understanding of the heterogeneity of BC, provide comprehensive insight into the correlation between cancer metabolism and chemotherapy resistance, and enable the prediction of immunotherapy responses based on T-cell heterogeneity.
Collapse
Affiliation(s)
- Shicong Tang
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China.
| | - Qing Wang
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Ke Sun
- State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan, 650500, People's Republic of China
- Yunnan Key Laboratory of Primate Biomedical Research, Kunming, Yunnan, 650500, People's Republic of China
| | - Ying Song
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Rui Liu
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Xin Tan
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Huimeng Li
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Yafeng Lv
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Fuying Yang
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Jiawen Zhao
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Sijia Li
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Pingping Bi
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Jiali Yang
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Zhengna Zhu
- State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan, 650500, People's Republic of China
| | - Dong Chen
- Department of Ultrasound, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Zhirui Chuan
- Department of Ultrasound, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Xiaomao Luo
- Department of Ultrasound, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Zaoxiu Hu
- Department of Pathology, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Ying Liu
- Department of Pathology, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Zhenhui Li
- Department of Radiology, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Tengfei Ke
- Department of Radiology, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Dewei Jiang
- Key Laboratory of Animal Models and Human, Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, China
- Kunming College of Life Sciences, University of Chinese Academy Sciences, Kunming, Yunnan, China
| | - Kai Zheng
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China
| | - Rirong Yang
- Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China.
- Department of Immunology, School of Basic Medical Sciences, Guangxi Medical University, Guangxi, 530021, People's Republic of China.
| | - Kai Chen
- State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan, 650500, People's Republic of China.
- Yunnan Key Laboratory of Primate Biomedical Research, Kunming, Yunnan, 650500, People's Republic of China.
| | - Rong Guo
- Department of Breast Surgery, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, People's Republic of China.
| |
Collapse
|
3
|
Xia X, Zhao S, Chen W, Xu C, Zhao D. CCT6A promotes esophageal squamous cell carcinoma cell proliferation, invasion and epithelial-mesenchymal transition by activating TGF-β/Smad/c-Myc pathway. Ir J Med Sci 2023; 192:2653-2660. [PMID: 37017854 DOI: 10.1007/s11845-023-03357-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 03/28/2023] [Indexed: 04/06/2023]
Abstract
OBJECTIVE Chaperonin-containing TCP1 subunit 6A (CCT6A) facilitates several malignant cancer behaviors, but its regulation of esophageal squamous cell carcinoma (ESCC) has not been reported. This study aimed to investigate the effect of CCT6A on cell proliferation, apoptosis, invasion and epithelial-mesenchymal transition (EMT) and its interaction with the TGF-β/Smad/c-Myc pathway in ESCC. METHODS CCT6A expression was detected in ESCC and normal esophageal epithelial cell lines by RT‒qPCR and western blotting. Furthermore, CCT6A siRNA, negative control (NC) siRNA, CCT6A encoding plasmid and NC encoding plasmid were transfected into OE21 and TE-1 cells. Subsequently, CCT6A siRNA- and NC siRNA-transfected cells were treated with TGF-β for rescue experiments. Cell proliferation, apoptosis, invasion, and E-cadherin/N-cadherin and p-Smad2/p-Smad3/c-Myc expression were detected. RESULTS CCT6A expression was increased in KYSE-180, TE-1, TE-4 and OE21 cells compared with HET-1A cells. In both OE21 and TE-1 cells, CCT6A knockdown inhibited cell proliferation, invasion and N-cadherin expression while promoting cell apoptosis and E-cadherin expression; meanwhile, CCT6A overexpression had the opposite effects. Furthermore, in both OE21 and TE-1 cells, CCT6A knockdown decreased p-Smad2/Smad2, p-Smad3/Smad3 and c-Myc/GAPDH expression; CCT6A overexpression had the opposite effects. Next, TGF-β facilitated cell proliferation, invasion, and N-cadherin, p-Smad2/Smad2, p-Smad3/Smad2 and c-Myc/GAPDH expression while repressing cell apoptosis and E-cadherin expression in OE21 and TE-1 cells; importantly, TGF-β could compensate for the regulation of CCT6A knockdown on these activities. CONCLUSION CCT6A facilitates ESCC malignant activities by activating the TGF-β/Smad/c-Myc pathway, which sheds light on the identification of a possible therapeutic target in the management of ESCC.
Collapse
Affiliation(s)
- Xiuli Xia
- Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China
- Department of Gastroenterology, Handan Central Hospital, Handan, 056001, China
| | - Shushan Zhao
- Department of Gastroenterology, Handan Central Hospital, Handan, 056001, China
| | - Wenting Chen
- Department of Endoscopy Center, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, China
| | - Chao Xu
- Department of Gastroenterology, Handan Central Hospital, Handan, 056001, China
| | - Dongqiang Zhao
- Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
| |
Collapse
|
4
|
Zhou W, Zeng W, Zheng D, Yang X, Qing Y, Zhou C, Liu X. Construction of a prognostic model for lung adenocarcinoma based on heat shock protein-related genes and immune analysis. Cell Stress Chaperones 2023; 28:821-834. [PMID: 37691069 PMCID: PMC10746678 DOI: 10.1007/s12192-023-01374-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 08/07/2023] [Accepted: 08/20/2023] [Indexed: 09/12/2023] Open
Abstract
Lung adenocarcinoma (LUAD) represents a prevalent form of cancer, with low early diagnosis rates and high mortality rates, posing a global health challenge. Heat shock proteins (HSPs) assume a crucial role within the tumor immune microenvironment (TME) of LUAD. Here, a collection of 97 HSP-related genes (HSPGs) was assembled based on prior literature reports, of which 36 HSPGs were differentially expressed in LUAD. In The Cancer Genome Atlas (TCGA) cohort, we constructed a prognostic model for risk stratification and prognosis prediction by integrating 13 HSPGs. In addition, the prognostic significance and predictive efficacy of the HSP-related riskscore were examined and validated in the Gene Expression Omnibus (GEO) cohort. To facilitate the clinical use of this riskscore, we also established a nomogram scale by verifying its effectiveness through different methods. In light of these outcomes, we concluded a significant correlation between HSPs and TME in LUAD, and the riskscore can be a reliable prognostic indicator. Furthermore, this study evaluated the differences in immunophenoscore, tumor immune dysfunction and exclusion score, and sensitivity to several common chemotherapy drugs among LUAD individuals in different risk groups, which may aid in clinical decision-making for immune therapy and chemotherapy in LUAD individuals.
Collapse
Affiliation(s)
- Wangyan Zhou
- Department of Medical Record, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China
| | - Wei Zeng
- Department of Thoracic Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Jiefang Avenue 35, Hengyang City, 421001, Hunan Province, China
| | - Dayang Zheng
- Department of Thoracic Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Jiefang Avenue 35, Hengyang City, 421001, Hunan Province, China
| | - Xu Yang
- Department of Thoracic Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Jiefang Avenue 35, Hengyang City, 421001, Hunan Province, China
| | - Yongcheng Qing
- Department of Thoracic Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Jiefang Avenue 35, Hengyang City, 421001, Hunan Province, China
| | - Chunxiang Zhou
- Department of Thoracic Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Jiefang Avenue 35, Hengyang City, 421001, Hunan Province, China
| | - Xiang Liu
- Department of Thoracic Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Jiefang Avenue 35, Hengyang City, 421001, Hunan Province, China.
| |
Collapse
|
5
|
Zheng L, Chen X, Zhang L, Qin N, An J, Zhu J, Jin H, Tuo B. A potential tumor marker: Chaperonin containing TCP‑1 controls the development of malignant tumors (Review). Int J Oncol 2023; 63:106. [PMID: 37539774 PMCID: PMC10552740 DOI: 10.3892/ijo.2023.5554] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 07/21/2023] [Indexed: 08/05/2023] Open
Abstract
Due to concealment, high invasiveness and a lack of indicators, malignant tumors have emerged as one of the deadliest diseases worldwide and their incidence is rising yearly. Research has revealed that the chaperonin family member, chaperonin containing TCP‑1 (CCT), serves a crucial role in malignant tumors. CCT is involved in the growth of numerous malignant tumors such as lung cancer, breast cancer, hepatocellular carcinoma and colorectal cancer and assists the folding of a number of proteins linked to cancer, such as KRAS, p53 and STAT3. According to clinical data, CCT is highly expressed in a range of tumor cells and is associated with poor patient prognosis. In addition, through controlling the cell cycle or interacting with other proteins (including YAP1, HoXB2 and SMAD2), CCT has an effect on the proliferation, invasion and migration of cancer cells. As a result, it is possible that CCT will become a new tumor marker or therapeutic target, which will provide some guidance for early tumor screening or late tumor prognosis. In the present review, the molecular properties of CCT are introduced, alongside a summary of its interactions with other cancer‑related proteins and a discussion of its function in common malignant tumors. It is expected that the present review will offer fresh approaches to the treatment of cancer.
Collapse
Affiliation(s)
- Liming Zheng
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003
| | - Xingyue Chen
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003
| | - Li Zhang
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003
| | - Nannan Qin
- Department of Critical Care Medicine of the First People's Hospital of Zunyi (The Third Affiliated Hospital), Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China
| | - Jiaxing An
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003
| | - Jiaxing Zhu
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003
| | - Hai Jin
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003
| | - Biguang Tuo
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003
| |
Collapse
|
6
|
Zhao W, Xi L, Yu G, Wang G, Chang C. High expression of GPR50 promotes the proliferation, migration and autophagy of hepatocellular carcinoma cells in vitro. J Cell Commun Signal 2023:10.1007/s12079-023-00772-9. [PMID: 37378811 DOI: 10.1007/s12079-023-00772-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2022] [Accepted: 05/29/2023] [Indexed: 06/29/2023] Open
Abstract
G protein-coupled receptors (GPCRs) play important roles in tumorigenesis and the development of hepatocellular carcinoma (HCC). GPR50 is an orphan GPCR. Previous studies have indicated that GPR50 could protect against breast cancer development and decrease tumor growth in a xenograft mouse model. However, its role in HCC remains indistinct. To detect the role and the regulation mechanism of GPR50 in HCC, GPR50 expression was analyzed in HCC patients (gene expression omnibus database (GEO) (GSE45436)) and detected in HCC cell line CBRH-7919, and the results showed that GPR50 was significantly up-regulated in HCC patients and CBRH-7919 cell line compared to the corresponding normal control. Gpr50 cDNA was transfected into HCC cell line CBRH-7919, and we found that Gpr50 promoted the proliferation, migration, and autophagy of CBRH-7919. The regulation mechanism of GPR50 in HCC was detected by isobaric tags for relative and absolute quantification (iTRAQ) analysis, and we found that GPR50 promoted HCC was closely related to CCT6A and PGK1. Taken together, GPR50 may promote HCC progression via CCT6A-induced proliferation and PGK1-induced migration and autophagy, and GPR50 could be an important target for HCC.
Collapse
Affiliation(s)
- Weiming Zhao
- College of Life Sciences, State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, Institute of Biomedical Science, Henan Normal University, Henan Xinxiang, 453007, China
| | - Lingling Xi
- Institute of Regenerative Medicine and Orthopedics, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453003, China
| | - Guoying Yu
- College of Life Sciences, State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, Institute of Biomedical Science, Henan Normal University, Henan Xinxiang, 453007, China
| | - Gaiping Wang
- College of Life Sciences, State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, Institute of Biomedical Science, Henan Normal University, Henan Xinxiang, 453007, China
| | - Cuifang Chang
- College of Life Sciences, State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, Institute of Biomedical Science, Henan Normal University, Henan Xinxiang, 453007, China.
| |
Collapse
|
7
|
Zhong J, Shen X, Zhou J, Yu H, Wang B, Sun J, Wang J, Liu F. Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer. Front Oncol 2023; 13:1077342. [PMID: 36998462 PMCID: PMC10043308 DOI: 10.3389/fonc.2023.1077342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2022] [Accepted: 02/23/2023] [Indexed: 03/17/2023] Open
Abstract
BackgroundHypoxia is involved in tumor biological processes and disease progression. Ferroptosis, as a newly discovered programmed cell death process, is closely related to breast cancer (BC) occurrence and development. However, reliable prognostic signatures based on a combination of hypoxia and ferroptosis in BC have not been developed.MethodWe set The Cancer Genome Atlas (TCGA) breast cancer cohort as training set and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) BC cohort as the validation set. Least Absolute Shrinkage and Selection Operator (LASSO) and COX regression approaches were used to construct ferroptosis-related genes (FRGs) and hypoxia-related genes (HRGs) prognostic signature (HFRS). The CIBERSORT algorithm and ESTIMATE score were used to explore the relationship between HFRS and tumor immune microenvironment. Immunohistochemical staining was used to detect protein expression in tissue samples. A nomogram was developed to advance the clinical application of HFRS signature.ResultsTen ferroptosis-related genes and hypoxia-related genes were screened to construct the HFRS prognostic signature in TCGA BC cohort, and the predictive capacity was verified in METABRIC BC cohort. BC patients with high-HFRS had shorter survival time, higher tumor stage, and a higher rate of positive lymph node. Moreover, high HFRS was associated with high hypoxia, ferroptosis, and immunosuppression status. A nomogram that was constructed with age, stage, and HFRS signature showed a strong prognostic capability to predict overall survival (OS) for BC patients.ConclusionWe developed a novel prognostic model with hypoxia and ferroptosis-related genes to predict OS, and characterize the immune microenvironment of BC patients, which might provide new cures for clinical decision-making and individual treatment of BC patients.
Collapse
Affiliation(s)
- Jianxin Zhong
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Xi Shen
- Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Junjie Zhou
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Heping Yu
- Department of Thyroid and Breast Surgery, Wuhan Fourth Hospital, Wuhan, China
| | - Birong Wang
- Department of Thyroid and Breast Surgery, Wuhan Fourth Hospital, Wuhan, China
| | - Jianbin Sun
- Department of Thyroid and Breast Surgery, Wuhan Fourth Hospital, Wuhan, China
| | - Jing Wang
- Department of Thoracic Surgery, Wuhan Fourth Hospital, Wuhan, China
- *Correspondence: Jing Wang, ; Feng Liu,
| | - Feng Liu
- Department of Thyroid and Breast Surgery, Wuhan Fourth Hospital, Wuhan, China
- *Correspondence: Jing Wang, ; Feng Liu,
| |
Collapse
|
8
|
CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma. DISEASE MARKERS 2022; 2022:1560199. [PMID: 35937942 PMCID: PMC9352476 DOI: 10.1155/2022/1560199] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Accepted: 07/13/2022] [Indexed: 11/17/2022]
Abstract
Chaperonin containing TCP1 subunit 6A (CCT6A) and coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2) are located at the chromosome 7p11 region proximal to epidermal growth factor receptor (EGFR). However, the amplifications, expressions, and the prognostic effects of CCT6A and CHCDH2 in lung adenocarcinoma (LUAD) are unclear. Here, using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, we found that CCT6A was coamplified and coexpressed with EGFR in LUAD patients. CCT6A amplification was correlated with the unfavorable outcomes of LUAD. Moreover, CCT6A was upregulated in LUAD tissues, and CCT6A overexpression was correlated with the unfavorable relapse free survival or overall survival of LUAD. On the contrary, CCT6A was hypomethylated in LUAD, and CCT6A hypermethylation was correlated with the favorable overall survival of LUAD. Similar expression and methylation profiling of CCT6A were obtained in 479 lung normal tissues and 544 LUAD tissues collected from 11 independent datasets. In 1,462 LUAD patients from eight independent cohorts, CCT6A was also correlated with LUAD relapse-free survival or overall survival. Furthermore, CCT6A overexpression promoted the cell growth and invasion of LUAD. Identification of genes differentially expressed in CCT6A highly expressed LUAD patients revealed that CHCHD2 was the most correlated with CCT6A expression. CHCHD2 was coamplified with CCT6A. CHCHD2 was upregulated in LUAD tissues, and overexpression of CHCHD2 was correlated with the shorted relapse-free survival or overall survival of LUAD. Overall, our results revealed that CCT6A and CHCHD2 were coamplifying and coexpressing with EGFR and were correlated with the unfavorable clinical outcomes of LUAD.
Collapse
|
9
|
Identification of a Novel Risk Model: A Five-Gene Prognostic Signature for Pancreatic Cancer. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2022; 2022:3660110. [PMID: 35845587 PMCID: PMC9286972 DOI: 10.1155/2022/3660110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 06/14/2022] [Accepted: 06/15/2022] [Indexed: 12/24/2022]
Abstract
Objective. Biomarkers for pancreatic cancer (PCa) prognosis provide evidence for improving the survival outcome of this disease. This study aimed to identify a prognostic risk model based on gene expression profiling of microarray bioinformatics analysis. Methods. Prognostic immune genes in the TCGA-PAAD cohort were identified using the univariate Cox regression and Kaplan–Meier survival analysis. Multivariate Cox regression (stepAIC) was used to identify prognostic genes from the top 20 hub genes in the protein-protein interaction (PPI) network. A prognostic risk model was established and its performance in predicting the overall survival in PCa was validated in GSE62452. Gene mutations and infiltration immune cells in PCa tumors were analyzed using online databases. Results. Univariate Cox regression and Kaplan–Meier survival analyses identified 128 prognostic genes. Multivariate Cox regression (stepAIC) identified five prognostic genes (PLCG1, MET, TNFSF10, CXCL9, and TLR3) out of the 20 hub genes in the PPI network. A prognostic risk model was established using the signature of five genes. This model had moderate to high accuracies (AUC > 0.700) in predicting 3-year and 5-year overall survival in TCGA and GSE62452 cohorts. The Kaplan–Meier survival analysis showed that high-risk scores were correlated with poor survival outcomes in PCa (
). Also, mutations in the five genes were related to poor survival. The five genes were related to multiple immune cells. Conclusions. The prognostic risk model was significantly correlated with the survival in PCa patients. This model modulated PCa tumor progression and prognosis by regulating immune cell infiltration.
Collapse
|
10
|
Ghozlan H, Cox A, Nierenberg D, King S, Khaled AR. The TRiCky Business of Protein Folding in Health and Disease. Front Cell Dev Biol 2022; 10:906530. [PMID: 35602608 PMCID: PMC9117761 DOI: 10.3389/fcell.2022.906530] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 04/20/2022] [Indexed: 01/03/2023] Open
Abstract
Maintenance of the cellular proteome or proteostasis is an essential process that when deregulated leads to diseases like neurological disorders and cancer. Central to proteostasis are the molecular chaperones that fold proteins into functional 3-dimensional (3D) shapes and prevent protein aggregation. Chaperonins, a family of chaperones found in all lineages of organisms, are efficient machines that fold proteins within central cavities. The eukaryotic Chaperonin Containing TCP1 (CCT), also known as Tailless complex polypeptide 1 (TCP-1) Ring Complex (TRiC), is a multi-subunit molecular complex that folds the obligate substrates, actin, and tubulin. But more than folding cytoskeletal proteins, CCT differs from most chaperones in its ability to fold proteins larger than its central folding chamber and in a sequential manner that enables it to tackle proteins with complex topologies or very large proteins and complexes. Unique features of CCT include an asymmetry of charges and ATP affinities across the eight subunits that form the hetero-oligomeric complex. Variable substrate binding capacities endow CCT with a plasticity that developed as the chaperonin evolved with eukaryotes and acquired functional capacity in the densely packed intracellular environment. Given the decades of discovery on the structure and function of CCT, much remains unknown such as the scope of its interactome. New findings on the role of CCT in disease, and potential for diagnostic and therapeutic uses, heighten the need to better understand the function of this essential molecular chaperone. Clues as to how CCT causes cancer or neurological disorders lie in the early studies of the chaperonin that form a foundational knowledgebase. In this review, we span the decades of CCT discoveries to provide critical context to the continued research on the diverse capacities in health and disease of this essential protein-folding complex.
Collapse
Affiliation(s)
- Heba Ghozlan
- Division of Cancer Research, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States
- Department of Physiology and Biochemistry, Jordan University of Science and Technology, Irbid, Jordan
| | - Amanda Cox
- Division of Cancer Research, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States
| | - Daniel Nierenberg
- Division of Cancer Research, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States
| | - Stephen King
- Division of Neuroscience, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States
| | - Annette R. Khaled
- Division of Cancer Research, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States
| |
Collapse
|
11
|
Belousov PV. The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges. Biomedicines 2022; 10:biomedicines10020468. [PMID: 35203677 PMCID: PMC8962333 DOI: 10.3390/biomedicines10020468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 02/06/2022] [Accepted: 02/07/2022] [Indexed: 11/24/2022] Open
Abstract
The Autoantibodies targeting Tumor-Associated Antigens (TAA-AAbs) emerge as a result of a variety of tumor-related immunogenic stimuli and may be regarded as the eyewitnesses to the anti-tumor immune response. TAA-AAbs may be readily detected in peripheral blood to unveil the presence of a particular TAA-expressing tumor, and a fair number of TAAs eliciting the tumor-associated autoantibody response have been identified. The potential of TAA-AAbs as tumor biomarkers has been extensively studied in many human malignancies with a major influence on public health; however, tumors of the endocrine system, and, in particular, the well-differentiated follicular cell-derived thyroid neoplasms, remain understudied in this context. This review provides a detailed perspective on and legitimate rationales for the potential use of TAA-AAbs in thyroid neoplasia, with particular reference to the already established diagnostic implications of the TAA-AAbs in human cancer, to the windows for improvement and diagnostic niches in the current workup strategies in nodular thyroid disease and differentiated thyroid cancer that TAA-AAbs may successfully occupy, as well as to the proof-of-concept studies demonstrating the usefulness of TAA-AAbs in thyroid oncology, particularly for the pre-surgical discrimination between tumors of different malignant potential in the context of the indeterminate results of the fine-needle aspiration cytology.
Collapse
Affiliation(s)
- Pavel V. Belousov
- National Center for Personalized Medicine of Endocrine Diseases, National Medical Research Center for Endocrinology, Ministry of Health of the Russian Federation, 117036 Moscow, Russia; or
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
| |
Collapse
|
12
|
Huang X, Wang H, Xu F, Lv L, Wang R, Jiang B, Liu T, Hu H, Jiang Y. Overexpression of chaperonin containing TCP1 subunit 7 has diagnostic and prognostic value for hepatocellular carcinoma. Aging (Albany NY) 2022; 14:747-769. [PMID: 35073517 PMCID: PMC8833116 DOI: 10.18632/aging.203809] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 12/20/2021] [Indexed: 11/25/2022]
Abstract
Chaperonin containing TCP1 subunit 7 (CCT7) regulates the expression of many tumor-related proteins. We investigated the diagnostic and prognostic value of CCT7 expression for hepatocellular carcinoma (HCC). In datasets from The Cancer Genome Atlas and the Gene Expression Omnibus, CCT7 mRNA levels were greater in HCC tissues than adjacent normal tissues, and these results were validated using immunohistochemistry. In patients with early-stage disease and low alpha-fetoprotein expression, CCT7 expression was still higher in HCC tissues than normal tissues. Receiver operating characteristic curve analyses indicated that CCT7 expression had better diagnostic value than alpha-fetoprotein for HCC patients with early-stage disease and low alpha-fetoprotein expression. The positive predictive value of CCT7 expression was higher than that of alpha-fetoprotein expression. Higher CCT7 mRNA and protein levels were independent risk factors for poorer overall and recurrence-free survival in HCC patients. Greater methylation of the CpG site cg19515186 was associated with better overall survival in HCC patients. Genes co-expressed with CCT7 were upregulated in HCC and associated with poorer overall survival. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes and Gene Set Enrichment Analyses demonstrated that CCT7 expression correlated with spliceosome signaling. These findings demonstrate that CCT7 has diagnostic and prognostic value for HCC.
Collapse
Affiliation(s)
- Xinghua Huang
- The Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, PR China.,Department of Hepatobiliary Surgery, 900th Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, PR China
| | - Huaxiang Wang
- The Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, PR China.,Department of Hepatobiliary and Pancreatic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China
| | - Fengfeng Xu
- The Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, PR China.,Department of Hepatobiliary Surgery, 900th Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, PR China
| | - Lizhi Lv
- The Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, PR China.,Department of Hepatobiliary Surgery, 900th Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, PR China
| | - Ruling Wang
- Department of Hepatobiliary and Pancreatic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China
| | - Bin Jiang
- Department of Hepatobiliary and Pancreatic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China
| | - Tingting Liu
- Department of Hepatobiliary Surgery, 900th Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, PR China.,Graduate School of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350025, PR China
| | - Huanzhang Hu
- The Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, PR China.,Department of Hepatobiliary Surgery, 900th Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, PR China
| | - Yi Jiang
- The Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, PR China.,Department of Hepatobiliary Surgery, 900th Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, PR China
| |
Collapse
|
13
|
Gallegos-Cabriales EC, Rodriguez-Ayala E, Laviada-Molina HA, Nava-Gonzalez EJ, Salinas-Osornio RA, Orozco L, Leal-Berumen I, Castillo-Pineda JC, Gonzalez-Lopez L, Escudero-Lourdes C, Cornejo-Barrera J, Escalante-Araiza F, Huerta-Avila EE, Buenfil-Rello FA, Peschard VG, Silva E, Veloz-Garza RA, Martinez-Hernandez A, Barajas-Olmos FM, Molina-Segui F, Gonzalez-Ramirez L, Arjona-Villicaña RD, Hernandez-Escalante VM, Gaytan-Saucedo JF, Vaquera Z, Acebo-Martinez M, Murillo-Ramirez A, Diaz-Tena SP, Figueroa-Nuñez B, Valencia-Rendon ME, Garzon-Zamora R, Viveros-Paredes JM, Valdovinos-Chavez SB, Comuzzie AG, Haack K, Thorsell AA, Han X, Cole SA, Bastarrachea RA. Replication of Integrative Data Analysis for Adipose Tissue Dysfunction, Low-Grade Inflammation, Postprandial Responses and OMICs Signatures in Symptom-Free Adults. BIOLOGY 2021; 10:1342. [PMID: 34943258 PMCID: PMC8698545 DOI: 10.3390/biology10121342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 12/11/2021] [Accepted: 12/12/2021] [Indexed: 11/16/2022]
Abstract
We previously reported preliminary characterization of adipose tissue (AT) dysfunction through the adiponectin/leptin ratio (ALR) and fasting/postprandial (F/P) gene expression in subcutaneous (SQ) adipose tissue (AT) biopsies obtained from participants in the GEMM study, a precision medicine research project. Here we present integrative data replication of previous findings from an increased number of GEMM symptom-free (SF) adults (N = 124) to improve characterization of early biomarkers for cardiovascular (CV)/immunometabolic risk in SF adults with AT dysfunction. We achieved this goal by taking advantage of the rich set of GEMM F/P 5 h time course data and three tissue samples collected at the same time and frequency on each adult participant (F/P blood, biopsies of SQAT and skeletal muscle (SKM)). We classified them with the presence/absence of AT dysfunction: low (<1) or high (>1) ALR. We also examined the presence of metabolically healthy (MH)/unhealthy (MUH) individuals through low-grade chronic subclinical inflammation (high sensitivity C-reactive protein (hsCRP)), whole body insulin sensitivity (Matsuda Index) and Metabolic Syndrome criteria in people with/without AT dysfunction. Molecular data directly measured from three tissues in a subset of participants allowed fine-scale multi-OMIC profiling of individual postprandial responses (RNA-seq in SKM and SQAT, miRNA from plasma exosomes and shotgun lipidomics in blood). Dynamic postprandial immunometabolic molecular endophenotypes were obtained to move towards a personalized, patient-defined medicine. This study offers an example of integrative translational research, which applies bench-to-bedside research to clinical medicine. Our F/P study design has the potential to characterize CV/immunometabolic early risk detection in support of precision medicine and discovery in SF individuals.
Collapse
Affiliation(s)
- Esther C. Gallegos-Cabriales
- Facultad de Enfermería, Universidad Autónoma de Nuevo León (UANL), Monterrey 64460, Mexico; (E.C.G.-C.); (R.A.V.-G.); (S.B.V.-C.)
| | - Ernesto Rodriguez-Ayala
- Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac Norte, Lomas Anahuac 52786, Mexico; (E.R.-A.); (F.E.-A.); (V.-G.P.); (E.S.)
| | - Hugo A. Laviada-Molina
- Escuela de Ciencias de la Salud, Universidad Marista de Mérida, Mérida 97300, Mexico; (H.A.L.-M.); (F.M.-S.); (L.G.-R.); (R.D.A.-V.); (V.M.H.-E.)
| | | | - Rocío A. Salinas-Osornio
- Departamento de Nutrición, Universidad del Valle de Atemajac (UNIVA), Zapopan 45050, Mexico; (R.A.S.-O.); (L.G.-L.); (M.E.V.-R.); (R.G.-Z.); (J.M.V.-P.)
| | - Lorena Orozco
- Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, SS, Ciudad de México 14610, Mexico; (L.O.); (E.E.H.-A.); (A.M.-H.); (F.M.B.-O.)
| | - Irene Leal-Berumen
- Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua, Chihuahua 31125, Mexico;
| | - Juan Carlos Castillo-Pineda
- Departamento de Nutrición Humana, Universidad Latina de América, Morelia 58170, Mexico; (J.C.C.-P.); (A.M.-R.); (S.P.D.-T.)
| | - Laura Gonzalez-Lopez
- Departamento de Nutrición, Universidad del Valle de Atemajac (UNIVA), Zapopan 45050, Mexico; (R.A.S.-O.); (L.G.-L.); (M.E.V.-R.); (R.G.-Z.); (J.M.V.-P.)
| | - Claudia Escudero-Lourdes
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosi 78240, Mexico; (C.E.-L.); (M.A.-M.)
| | - Judith Cornejo-Barrera
- Departamento de Enseñanza, Postgrado e Investigación, Hospital Infantil de Tamaulipas, Ciudad Victoria 87150, Mexico;
| | - Fabiola Escalante-Araiza
- Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac Norte, Lomas Anahuac 52786, Mexico; (E.R.-A.); (F.E.-A.); (V.-G.P.); (E.S.)
- Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, SS, Ciudad de México 14610, Mexico; (L.O.); (E.E.H.-A.); (A.M.-H.); (F.M.B.-O.)
| | - Eira E. Huerta-Avila
- Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, SS, Ciudad de México 14610, Mexico; (L.O.); (E.E.H.-A.); (A.M.-H.); (F.M.B.-O.)
| | - Fatima A. Buenfil-Rello
- Population Health Program, Southwest National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, TX 78227-0549, USA; (F.A.B.-R.); (J.F.G.-S.); (Z.V.); (K.H.); (S.A.C.)
| | - Vanessa-Giselle Peschard
- Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac Norte, Lomas Anahuac 52786, Mexico; (E.R.-A.); (F.E.-A.); (V.-G.P.); (E.S.)
| | - Eliud Silva
- Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac Norte, Lomas Anahuac 52786, Mexico; (E.R.-A.); (F.E.-A.); (V.-G.P.); (E.S.)
| | - Rosa A. Veloz-Garza
- Facultad de Enfermería, Universidad Autónoma de Nuevo León (UANL), Monterrey 64460, Mexico; (E.C.G.-C.); (R.A.V.-G.); (S.B.V.-C.)
| | - Angelica Martinez-Hernandez
- Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, SS, Ciudad de México 14610, Mexico; (L.O.); (E.E.H.-A.); (A.M.-H.); (F.M.B.-O.)
| | - Francisco M. Barajas-Olmos
- Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, SS, Ciudad de México 14610, Mexico; (L.O.); (E.E.H.-A.); (A.M.-H.); (F.M.B.-O.)
| | - Fernanda Molina-Segui
- Escuela de Ciencias de la Salud, Universidad Marista de Mérida, Mérida 97300, Mexico; (H.A.L.-M.); (F.M.-S.); (L.G.-R.); (R.D.A.-V.); (V.M.H.-E.)
| | - Lucia Gonzalez-Ramirez
- Escuela de Ciencias de la Salud, Universidad Marista de Mérida, Mérida 97300, Mexico; (H.A.L.-M.); (F.M.-S.); (L.G.-R.); (R.D.A.-V.); (V.M.H.-E.)
| | - Ruy D. Arjona-Villicaña
- Escuela de Ciencias de la Salud, Universidad Marista de Mérida, Mérida 97300, Mexico; (H.A.L.-M.); (F.M.-S.); (L.G.-R.); (R.D.A.-V.); (V.M.H.-E.)
| | - Victor M. Hernandez-Escalante
- Escuela de Ciencias de la Salud, Universidad Marista de Mérida, Mérida 97300, Mexico; (H.A.L.-M.); (F.M.-S.); (L.G.-R.); (R.D.A.-V.); (V.M.H.-E.)
| | - Janeth F. Gaytan-Saucedo
- Population Health Program, Southwest National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, TX 78227-0549, USA; (F.A.B.-R.); (J.F.G.-S.); (Z.V.); (K.H.); (S.A.C.)
| | - Zoila Vaquera
- Population Health Program, Southwest National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, TX 78227-0549, USA; (F.A.B.-R.); (J.F.G.-S.); (Z.V.); (K.H.); (S.A.C.)
| | - Monica Acebo-Martinez
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosi 78240, Mexico; (C.E.-L.); (M.A.-M.)
| | - Areli Murillo-Ramirez
- Departamento de Nutrición Humana, Universidad Latina de América, Morelia 58170, Mexico; (J.C.C.-P.); (A.M.-R.); (S.P.D.-T.)
| | - Sara P. Diaz-Tena
- Departamento de Nutrición Humana, Universidad Latina de América, Morelia 58170, Mexico; (J.C.C.-P.); (A.M.-R.); (S.P.D.-T.)
| | - Benigno Figueroa-Nuñez
- Clínica de Enfermedades Crónicas y Procedimientos Especiales (CECYPE), Morelia 58249, Mexico;
| | - Melesio E. Valencia-Rendon
- Departamento de Nutrición, Universidad del Valle de Atemajac (UNIVA), Zapopan 45050, Mexico; (R.A.S.-O.); (L.G.-L.); (M.E.V.-R.); (R.G.-Z.); (J.M.V.-P.)
| | - Rafael Garzon-Zamora
- Departamento de Nutrición, Universidad del Valle de Atemajac (UNIVA), Zapopan 45050, Mexico; (R.A.S.-O.); (L.G.-L.); (M.E.V.-R.); (R.G.-Z.); (J.M.V.-P.)
| | - Juan Manuel Viveros-Paredes
- Departamento de Nutrición, Universidad del Valle de Atemajac (UNIVA), Zapopan 45050, Mexico; (R.A.S.-O.); (L.G.-L.); (M.E.V.-R.); (R.G.-Z.); (J.M.V.-P.)
| | - Salvador B. Valdovinos-Chavez
- Facultad de Enfermería, Universidad Autónoma de Nuevo León (UANL), Monterrey 64460, Mexico; (E.C.G.-C.); (R.A.V.-G.); (S.B.V.-C.)
| | | | - Karin Haack
- Population Health Program, Southwest National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, TX 78227-0549, USA; (F.A.B.-R.); (J.F.G.-S.); (Z.V.); (K.H.); (S.A.C.)
| | | | - Xianlin Han
- Department of Medicine, Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX 78229, USA;
| | - Shelley A. Cole
- Population Health Program, Southwest National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, TX 78227-0549, USA; (F.A.B.-R.); (J.F.G.-S.); (Z.V.); (K.H.); (S.A.C.)
| | - Raul A. Bastarrachea
- Population Health Program, Southwest National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, TX 78227-0549, USA; (F.A.B.-R.); (J.F.G.-S.); (Z.V.); (K.H.); (S.A.C.)
- Sansum Diabetes Research Institute, Santa Barbara, CA 93105, USA;
| |
Collapse
|
14
|
Liu J, Huang L, Zhu Y, He Y, Zhang W, Lei T, Xuan J, Xiao B, Li L, Zhou Q, Sun Z. Exploring the Expression and Prognostic Value of the TCP1 Ring Complex in Hepatocellular Carcinoma and Overexpressing Its Subunit 5 Promotes HCC Tumorigenesis. Front Oncol 2021; 11:739660. [PMID: 34676169 PMCID: PMC8525800 DOI: 10.3389/fonc.2021.739660] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Accepted: 09/08/2021] [Indexed: 01/20/2023] Open
Abstract
T-complex protein-1 ring complex (TRiC), also known as Chaperonin Containing T-complex protein-1 (CCT), is a multisubunit chaperonin required for the folding of nascent proteins. Mounting evidence suggests that TRiC also contributes to the development and progression of tumors, but there are limited studies on pathogenic functions in hepatocellular carcinoma (HCC). We comprehensively evaluated the expression pattern and biological functions of TRiC subunits using The Cancer Genome Atlas and The Human Protein Atlas. Expression levels of TRiC subunits TCP1, CCT2/3/4/5/6A/7/8 were significantly upregulated in HCC tissues at both transcript and protein levels, which predicted shorter overall survival (OS). Moreover, high mutation rates were found in several CCT subunits, and patients with altered CCT genes exhibited poorer clinical outcomes. Functional enrichment analysis showed that co-regulated genes were preferentially involved in 'protein folding' and 'microtubule-based process', while genes co-expressed with CCT subunits were primarily involved in 'ribosome' and 'spliceosome'. Knockout of CCT5 in a HCC cell line reduced while overexpression enhanced proliferation rate, cycle transition, migration, and invasion. In conclusion, these findings suggest that subunits of the TRiC may be potential biomarkers for the diagnosis of HCC and play an important role in the occurrence and development of HCC.
Collapse
Affiliation(s)
- Jiahui Liu
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.,Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| | - Ling Huang
- Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| | - Yi Zhu
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.,Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| | - Yongyin He
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.,Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| | - Weiyun Zhang
- Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| | - Ting Lei
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.,Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| | - Junfeng Xuan
- Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| | - Bin Xiao
- Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China.,Qingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China
| | - Linhai Li
- Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China.,Qingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China
| | - Quan Zhou
- Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China.,Laboratory of Basic Medical Science, General Hospital of Southern Theater Command of PLA, Guangzhou, China
| | - Zhaohui Sun
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.,Department of Laboratory Medicine, General Hospital of Southern Theater Command of People's Liberation Army (PLA), Guangzhou, China
| |
Collapse
|
15
|
Hu Y, Fu P, Zhao H, Zhang F, Jiang X, Zhao W, Lv P. Chaperonin-containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients. J Clin Lab Anal 2021; 35:e23917. [PMID: 34312925 PMCID: PMC8418478 DOI: 10.1002/jcla.23917] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/06/2021] [Accepted: 07/12/2021] [Indexed: 12/15/2022] Open
Abstract
Objective Chaperonin‐containing tailless complex polypeptide 1 subunit 6A (CCT6A) is reported to be an efficient prognostic biomarker in various cancers, but it is rarely reported in astrocytoma. Thus, this study aimed to evaluate the expression of CCT6A and its correlation with disease features and prognosis in astrocytoma patients. Methods Totally, 198 astrocytoma patients who received surgery treatment were enrolled. CCT6A protein expression was determined in the tumor tissues fixed in formalin and embedded in paraffin (FFEP) by immunohistochemistry (IHC) assay. In addition, 133 out of 198 astrocytoma patients had fresh tumor tissues frozen in the liquid nitrogen for the determination of CCT6A mRNA expression by reverse transcription‐quantitative polymerase chain reaction. Results Sixty‐nine (34.8%), 70 (35.4%), 46 (23.2%), and 13 (6.6%) astrocytoma patients had the CCT6A immunohistochemistry (IHC) score of 0–3, 4–6, 7–9, and 10–12, respectively. CCT6A protein expression was correlated with increased World Health Organization (WHO) grade (P < 0.001) and less isocitrate dehydrogenase (IDH) mutation (P = 0.002); meanwhile, CCT6A mRNA expression was only related to elevated WHO grade (P = 0.001). However, CCT6A protein and mRNA expression were not correlated with other clinical features and subsequent treatment modalities (all P > 0.05). Moreover, CCT6A protein high and CCT6A mRNA high were related to shorter accumulating overall survival (OS; both P < 0.05). CCT6A protein high was an independent factor for predicting the worse OS (hazard ratio: 1.821, P = 0.012). Conclusion Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with elevated WHO grade and less IDH mutation; besides, CCT6A high expression is independently associated with unfavorable accumulating OS of astrocytoma patients.
Collapse
Affiliation(s)
- Yueyun Hu
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Peng Fu
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Hongyang Zhao
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Fangcheng Zhang
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xiaobing Jiang
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Wohua Zhao
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Peng Lv
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Neurosurgery, Suizhou Hospital, Hubei University of Medicine, Suizhou, China
| |
Collapse
|
16
|
Sun H, Wang Y, Jing HY, Yang XY, Shi XX, Zhang JH, Yu YX, Gao L, Wang XY, Li WH, Yu L. Chaperonin-Containing TCP1 Subunit 6A Is a Prognostic Potential Biomarker That Correlates With the Presence of Immune Infiltrates in Colorectal Cancer. Front Genet 2021; 12:629856. [PMID: 34017352 PMCID: PMC8129517 DOI: 10.3389/fgene.2021.629856] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 03/23/2021] [Indexed: 01/17/2023] Open
Abstract
Aims Chaperonin-containing TCP1 subunit (CCT) 6A is an oncogenic 6th subunit of the CCT family. Nevertheless, not much is documented regarding its function in colorectal cancer (COAD). This investigation seeks to explore the role of CCT6A in the prognosis of COAD. Main Methods Sequencing data from the Gene Expression Omnibus (GEO) and Cancer Genome Atlas database (TCGA) were employed to analyze the expression of CCT6A and its involvement in various regulatory networks behind COAD. Oncomine and Gene Expression Profiling Interactive Analysis (GEPIA) analyzed Levels of expression and survival rates, while GEPIA was used to uncover further the functional networks that involved CCT6A. Database for Annotation, Visualization, and Integrated Discovery (DAVID) tools were used to interpret Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways. Evaluation of the expression levels of CCT6A in COAD samples was also verified via immunohistochemistry. Key Findings We found that the expression of CCT6A is up-regulated in COAD. CCT6A correlated with poor prognosis and decreased immune infiltrates such as CD4+ T cells, B cells, and dendritic cells. CCT6A is increased in COAD patients. CCT6A is associated with several gene networks related to the DDX family and mismatch repair pathways. Significance Our data showed that data mining was able to uncover data regarding levels of CCT6A and its involvement in genetic regulating pathways in COAD.
Collapse
Affiliation(s)
- Hui Sun
- College of Pharmacy, Harbin Medical University, Harbin, China.,Pharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University, Harbin, China
| | - Yan Wang
- College of Pharmacy, Harbin Medical University, Harbin, China
| | - Hao-Yu Jing
- Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Xin-Yu Yang
- College of Pharmacy, Harbin Medical University, Harbin, China
| | - Xin-Xiu Shi
- College of Pharmacy, Harbin Medical University, Harbin, China
| | - Jia-Hui Zhang
- College of Pharmacy, Harbin Medical University, Harbin, China
| | - Yuan-Xiu Yu
- College of Pharmacy, Harbin Medical University, Harbin, China
| | - Li Gao
- Department of Oral and Maxillofacial Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Xin-Yue Wang
- College of Pharmacy, Harbin Medical University, Harbin, China
| | - Wan-Hong Li
- College of Pharmacy, Harbin Medical University, Harbin, China
| | - Lei Yu
- Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| |
Collapse
|
17
|
Li W, Liu J, Zhao H. Prognostic Power of a Chaperonin Containing TCP-1 Subunit Genes Panel for Hepatocellular Carcinoma. Front Genet 2021; 12:668871. [PMID: 33897772 PMCID: PMC8061729 DOI: 10.3389/fgene.2021.668871] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 03/15/2021] [Indexed: 02/05/2023] Open
Abstract
Chaperonin containing TCP-1 (T-complex protein 1) (CCT) is a large molecular weight complex that contains nine subunits (TCP1, CCT2, CCT3, CCT4, CCT5, CCT6A, CCT6B, CCT7, CCT8). This study aimed to reveal key genes which encode CCT subunits for prognosis and establish prognostic gene signatures based on CCT subunit genes. The data was downloaded from The Cancer Genome Atlas, International Cancer Genome Consortium and Gene Expression Omnibus. CCT subunit gene expression levels between tumor and normal tissues were compared. Corresponding Kaplan-Meier analysis displayed a distinct separation in the overall survival of CCT subunit genes. Correlation analysis, protein-protein interaction network, Gene Ontology analysis, immune cells infiltration analysis, and transcription factor network were performed. A nomogram was constructed for the prediction of prognosis. Based on multivariate Cox regression analysis and shrinkage and selection method for linear regression model, a three-gene signature comprising CCT4, CCT6A, and CCT6B was constructed in the training set and significantly associated with prognosis as an independent prognostic factor. The prognostic value of the signature was then validated in the validation and testing set. Nomogram including the signature showed some clinical benefit for overall survival prediction. In all, we built a novel three-gene signature and nomogram from CCT subunit genes to predict the prognosis of hepatocellular carcinoma, which may support the medical decision for HCC therapy.
Collapse
Affiliation(s)
- Wenli Li
- Reproductive Medicine Center, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China
| | - Jun Liu
- Reproductive Medicine Center, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China
| | - Hetong Zhao
- Department of Traditional Chinese Medicine, Changhai Hospital, Naval Military Medical University, Shanghai, China
- *Correspondence: Hetong Zhao
| |
Collapse
|
18
|
Zhang T, Shi W, Tian K, Kong Y. Chaperonin containing t-complex polypeptide 1 subunit 6A correlates with lymph node metastasis, abnormal carcinoembryonic antigen and poor survival profiles in non-small cell lung carcinoma. World J Surg Oncol 2020; 18:156. [PMID: 32631353 PMCID: PMC7339415 DOI: 10.1186/s12957-020-01911-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2020] [Accepted: 06/10/2020] [Indexed: 12/25/2022] Open
Abstract
Background This study aimed to investigate the correlation of chaperonin containing t-complex polypeptide 1 subunit 6A (CCT6A) expression with clinicopathological features and survival profiles in non-small cell lung carcinoma (NSCLC) patients. Methods A total of 381 NSCLC patients with Tumor, Node, Metastasis (TNM) stage I–IIIA who underwent tumor resection were retrospectively screened. Immunohistochemistry staining and semi-quantitative scoring were used to evaluate CCT6A expression in tumor and adjacent tissues. Clinicopathological features were retrieved. Disease-free survival (DFS) and overall survival (OS) were calculated. Results CCT6A expression was elevated in tumor tissue (CCT6A high 47.5% vs. low 52.5%) compared with adjacent tissue (CCT6A high 30.4% vs. low 69.6%) (P < 0.001), and ROC curve displayed that CCT6A could distinguish tumor tissue from adjacent tissue. Moreover, tumor CCT6A high expression was associated with lymph node metastasis (P = 0.001), elevated TNM stage (P = 0.002), and abnormal carcinoembryonic antigen (P = 0.022). Kaplan–Meier curves displayed that tumor CCT6A high expression was negatively correlated with DFS and OS (all P < 0.001). Cox’s regression analysis disclosed that tumor CCT6A high expression independently predicted worse DFS (P < 0.001) (hazard ratio (HR) 1.659 (95% confidence interval (CI) 1.318–2.089)), and OS (P < 0.001) (HR 1.779 (95%CI 1.378–2.298)). Conclusions CCT6A may present some clinical value in the management of NSCLC.
Collapse
Affiliation(s)
- Ting Zhang
- Department of Pulmonary and Critical Care Medicine, Affiliated Nanhua Hospital, University of South China, 336 South of Dongfeng Road, Hengyang, 421000, China
| | - Wang Shi
- Department of Pulmonary and Critical Care Medicine, Affiliated Nanhua Hospital, University of South China, 336 South of Dongfeng Road, Hengyang, 421000, China.
| | - Ke Tian
- Department of Pulmonary and Critical Care Medicine, Affiliated Nanhua Hospital, University of South China, 336 South of Dongfeng Road, Hengyang, 421000, China
| | - Yushan Kong
- Department of Pulmonary and Critical Care Medicine, Affiliated Nanhua Hospital, University of South China, 336 South of Dongfeng Road, Hengyang, 421000, China
| |
Collapse
|